CN111906328B - A kind of 177 Lu-labeled gold nanocluster and preparation method and application thereof - Google Patents
A kind of 177 Lu-labeled gold nanocluster and preparation method and application thereof Download PDFInfo
- Publication number
- CN111906328B CN111906328B CN202010803689.7A CN202010803689A CN111906328B CN 111906328 B CN111906328 B CN 111906328B CN 202010803689 A CN202010803689 A CN 202010803689A CN 111906328 B CN111906328 B CN 111906328B
- Authority
- CN
- China
- Prior art keywords
- gold nanoclusters
- gold
- labeled
- glutathione
- nanoclusters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/07—Metallic powder characterised by particles having a nanoscale microstructure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Abstract
The invention belongs to the technical field of radioisotope labeling and provides a method for preparing a radioisotope label 177 The preparation method of the Lu-labeled gold nanocluster comprises the steps of reducing chloroauric acid by using glutathione to obtain the gold nanocluster; by using 177 LuCl 3 The gold nanoclusters are marked by hydrochloric acid eluent to obtain 177 Lu-labeled gold nanoclusters. The gold nanoclusters of the invention can be paired 177 Labeling Lu for stabilization; compared with the simple nuclide, the nuclide marked on the gold nanocluster is easier to enrich and retain at the tumor cell part, 177 the anti-tumor drug prepared from the Lu-labeled gold nanoclusters has very good application value.
Description
Technical Field
The invention relates to the technical field of radioactive isotope labeling, in particular to a radioactive isotope labeling method 177 Lu-marked gold nanoclusters and a preparation method and application thereof.
Background
Today cancer remains one of the leading causes of human death worldwide. Despite the tremendous advances in cancer biology, oncology, surgical techniques, etc. in recent years, radiation therapy, including both External Beam Radiation Therapy (EBRT) and internal radioisotope therapy, has been widely used in clinical cancer therapy. However, high doses of ionizing radiation are often required during radiotherapy, which results in severe damage to normal tissue adjacent to the tumor; meanwhile, the efficacy of radiotherapy is limited by different mechanisms.
With the development of nanotechnology, there has been a great interest in enhancing the effect of radiotherapy based on Nanomedicine. The radiation absorbing nanomaterials can be used as radiosensitizers to deposit radiant energy within tumors and enhance therapeutic efficacy or to modulate the tumor microenvironment by nanomaterials to overcome the radiation resistance associated with hypoxia. Meanwhile, the nano-carrier can also deliver the therapeutic radioactive isotope to the tumor part to realize the combination of internal radiotherapy or the radiotherapy and the chemotherapy by cooperating with a chemotherapeutic drug. In addition, it has been reported that secondary electrons can be generated by the interaction between the radioisotope and high atomic number, and have an obvious effect on enhancing internal radiotherapy.
Therefore, the research and development of the anti-tumor drug prepared from the nuclide-labeled gold nanocluster have great social value and wide market prospect.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a method 177 Lu-labeled gold nanoclusters and a preparation method and application thereof. The invention stably marks the gold nanoclusters by a chelation method 177 Compared with a simple nuclide, the Lu radionuclide marked on the gold nanocluster is easier to enrich and retain at a tumor cell part.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a 177 A method for preparing Lu-labeled gold nanoclusters comprising the steps of:
1) Reducing chloroauric acid by using glutathione to obtain gold nanoclusters;
2) By using 177 LuCl 3 The gold nanoclusters are marked by hydrochloric acid eluent to obtain 177 Lu-labeled gold nanoclusters.
Preferably, the molar ratio of the glutathione to the chloroauric acid in the step 1) is 3-5:4-6, the glutathione is a glutathione aqueous solution, and the chloroauric acid is a chloroauric acid aqueous solution.
Preferably, the temperature of the reduction in the step 1) is 80-100 ℃ and the time is 25-40 min.
Preferably, the concentration of the glutathione aqueous solution is 40-60 mg/mL, and the concentration of the chloroauric acid aqueous solution is 0.5-1.5 mol/L.
Preferably, the reaction solution is filtered after the reduction in step 1) is completed, and the pH of the filtrate is adjusted to 2 to 5, and then the filtrate is subjected to centrifugal concentration to obtain gold nanoclusters.
Preferably, step 2) is as described 177 LuCl 3 The activity of the hydrochloric acid eluent is 1-3 mCi, the concentration of the gold nanocluster is 30-40 mg/mL, and the gold nanocluster is prepared by the steps of 177 LuCl 3 The volume ratio of the hydrochloric acid eluent to the gold nanoclusters is 3.
Preferably, the labeling of step 2) is 177 LuCl 3 The pH value of the hydrochloric acid eluent is adjusted to 5-6, and then the gold nanoclusters are marked for 20-40 min.
The invention also provides the 177 Prepared by the method for preparing Lu-marked gold nanocluster 177 Lu-labeled gold nanoclusters.
The invention also provides the 177 The application of the Lu-labeled gold nanoclusters in preparing antitumor drugs.
Preferably, the tumor is 4T1.
The beneficial effects of the invention include:
according to the invention 177 The Lu-marked gold nanocluster is composed of radioactive nuclide 177 Lu is chelated to glutathione-modified gold nanoclusters to form. The gold nanoclusters may be paired 177 Labeling Lu for stabilization; compared with the simple nuclide, the nuclide marked on the gold nanocluster is easier to enrich and retain at the tumor cell part, 177 the anti-tumor drug prepared from the Lu-labeled gold nanoclusters has very good application value.
Drawings
FIG. 1 is a drawing of example 1 177 Schematic diagram of medicine prepared from Lu-labeled gold nanoclusters for resisting tumor.
Fig. 2 is a transmission electron micrograph of glutathione-modified gold nanoclusters of example 1.
FIG. 3 is a drawing showing a structure of example 1 177 Stability testing of Lu-labeled gold nanoclusters.
FIG. 4 shows the results of example 1 177 Liquid flash test plots of Lu-labeled gold nanoclusters.
FIG. 5 shows gold nanoclusters labeled with different nuclides of activity in application example 1 177 MTT evaluation chart of Lu.
FIG. 6 shows a single injection of the tail vein of application example 2 177 Mouse tumor inhibition profiles of Lu-labeled gold nanoclusters.
FIG. 7 is a schematic view of 177 H of mouse breast cancer tissue obtained by using Lu-labeled gold nanoclusters through different methods&E and Tunnel sections.
Detailed Description
The invention provides a 177 A method for preparing Lu-labeled gold nanoclusters, comprisingThe method comprises the following steps:
1) Reducing chloroauric acid by using glutathione to obtain gold nanoclusters;
2) By using 177 LuCl 3 The gold nanoclusters are marked by hydrochloric acid eluent to obtain 177 Lu-labeled gold nanoclusters.
The molar ratio of the glutathione to the chloroauric acid in the step 1) is preferably 3-5:4-6, and more preferably 4:5; the glutathione is preferably glutathione aqueous solution, and the chloroauric acid is preferably chloroauric acid aqueous solution.
The temperature of the reduction in the step 1) of the invention is preferably 80-100 ℃, and more preferably 90 ℃; the reduction time is preferably 25 to 40min, and more preferably 30min.
The concentration of the glutathione aqueous solution is preferably 40-60 mg/mL, and more preferably 50mg/mL; the concentration of the chloroauric acid aqueous solution is preferably 0.5-1.5 mol/L, and more preferably 1mol/L; the ratio of the volume of the glutathione aqueous solution to the volume of the chloroauric acid aqueous solution is preferably 461 to 1154, more preferably 600 to 800.
After the reduction in step 1) of the present invention is completed, the reaction solution is preferably filtered, and after the pH of the filtrate is preferably adjusted to 2 to 5, the gold nanoclusters are obtained by centrifugal concentration.
As described in step 2) of the present invention 177 LuCl 3 The activity of the hydrochloric acid eluent is preferably 1-3 mCi, and more preferably 2mCi; the concentration of the gold nanocluster concentrated solution is preferably 30-40 mg/mL, and more preferably 34.08mg/mL; the above-mentioned 177 LuCl 3 The volume ratio of the hydrochloric acid eluent to the gold nanoclusters is preferably 3.
The labeling in step 2) of the present invention is preferably 177 LuCl 3 The pH value of the hydrochloric acid eluent is adjusted to 5-6, and then the gold nanoclusters are marked, wherein the marking time is preferably 20-40 min, and more preferably 30min.
The invention also provides the 177 Production of Lu-labeled gold nanoclustersObtained by the method 177 Lu-labeled gold nanoclusters.
The invention also provides the 177 The application of the Lu-marked gold nanoclusters in preparing antitumor drugs.
The tumor of the invention is preferably 4T1.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
738 uL of Glutathione (GSH) aqueous solution with concentration of 50mg/mL and 150 uL of chloroauric acid (HAuCl) with concentration of 1mol/L 4 ·4H 2 O) the aqueous solution was quickly added to a single-neck flask containing 50mL deionized water with stirring, then the single-neck flask was sealed and quickly warmed to 90 ℃ and reacted at 90 ℃ for 30 minutes. After the reaction was completed and allowed to return to room temperature, the reaction solution was taken out and the larger particles were removed by using a 0.45 μm filter, and then the pH of the filtrate was adjusted to 3 by using 1mol/L NaOH aqueous solution, and the product was dispersed in PBS by centrifugal concentration using an ultrafiltration tube (3000 Da,5000 r/min) to obtain glutathione-modified gold nanoclusters (GSHAuNCs).
Using NaOH aqueous solution to prepare a solution with the activity of 2mCi and the volume of 0.02mL 177 LuCl 3 The pH of the eluate was adjusted to 6, 1mL of GSHAuNCs was added at a concentration of 34.08mg/mL, and after shaking for 30 minutes, the resulting mixture was centrifuged (3000 Da,4500 r/min) using an ultrafiltration tube to wash off the unlabeled material 177 Lu, obtained 177 Lu-labeled gold nanoclusters ( 177 Lu@AuNCs)。
As can be seen from the transmission electron micrograph of FIG. 2, the particle size of GSHAuNCs was about 2.5 nm.
From the stability test of FIG. 3, it can be seen that the gold nanocluster pair 177 The labeling stability of Lu is up to 88%.
As can be seen from the liquid scintillation meter test of figure 4, 177 in Lu-labeled gold nanoclusters 177 Lu can efficiently generate secondary electrons.
Example 2
650 uL Glutathione (GS) with a concentration of 55mg/mLH) Aqueous solution and 120. Mu.L of chloroauric acid (HAuCl) at a concentration of 1.5mol/L 4 ·4H 2 O) the aqueous solution was rapidly added to a single-neck flask containing 50mL of deionized water with stirring, and the single-neck flask was then sealed and rapidly warmed to 100 ℃ for 25 minutes at 100 ℃. After the reaction was completed and allowed to return to room temperature, the reaction solution was taken out and the larger particles were removed by using a 0.45 μm filter, and then the pH of the filtrate was adjusted to 3 by using 1mol/L NaOH aqueous solution, and the product was dispersed in PBS by centrifugal concentration using an ultrafiltration tube (3000 Da,5000 r/min) to obtain glutathione-modified gold nanoclusters (GSHAuNCs).
Using NaOH aqueous solution to make the mixture have the activity of 3mCi and the volume of 0.01mL 177 LuCl 3 Adjusting pH of the hydrochloric acid eluate to 5, adding 1mL of 30mg/mL GSHAuNCs, shaking for 40min, and centrifuging with ultrafiltration tube (3000Da, 4500 r/min) to remove unlabeled part 177 Lu, obtained 177 Lu-labeled gold nanoclusters ( 177 Lu@AuNCs)。
The particle diameter of GSHAuNCs is about 2.8nm, and the gold nanocluster pair 177 The labeling stability of Lu is as high as 90%, 177 in Lu-labeled gold nanoclusters 177 Lu can efficiently generate secondary electrons.
Example 3
900 μ L of Glutathione (GSH) aqueous solution with a concentration of 45mg/mL and 200 μ L of chloroauric acid (HAuCl) with a concentration of 0.8mol/L 4 ·4H 2 O) aqueous solution was rapidly added to a single-necked flask containing 50mL of deionized water under stirring, and then the single-necked flask was sealed and rapidly warmed to 80 ℃ and reacted at 80 ℃ for 40 minutes. After the reaction was completed and allowed to return to room temperature, the reaction solution was taken out and the larger particles were removed by using a 0.45 μm filter, and then the pH of the filtrate was adjusted to 4 by using a 1mol/L aqueous NaOH solution, and the product was dispersed in water by centrifugal concentration using an ultrafiltration tube (3000 Da,5000 r/min) to obtain glutathione-modified gold nanoclusters (GSHAuNCs).
Using NaOH aqueous solution to prepare the extract with the activity of 1mCi and the volume of 0.015mL 177 LuCl 3 Adjusting pH of hydrochloric acid eluate to 5, adding 1mL of 40mg/mL GSHAuNCs, shaking for 25 min, and separating with ultrafilterThe core (3000Da, 4500r/min) is washed off the unmarked part 177 Lu, obtained 177 Lu-labeled gold nanoclusters ( 177 Lu@AuNCs)。
The particle diameter of GSHAuNCs is about 2.3nm, and the gold nanocluster pair 177 The labeling stability of Lu is as high as 90%, 177 in Lu-labeled gold nanoclusters 177 Lu can efficiently generate secondary electrons.
Application example 1: 177 anti-tumor effect of Lu-labeled gold nanocluster in vitro
Mouse breast cancer cells (4T 1 cells) were digested and resuspended in culture medium, and after cell density was subsequently estimated by a hemocytometer, 4T1 cells were seeded into 96-well cell culture plates (5.0X 10) 3 Cells/well, 0.2 mL). Gold nanoclusters marked with different active nuclides of 0, 0.313 mu Ci, 0.613 mu Ci, 1.25 mu Ci, 2.5 mu Ci, 5 mu Ci and 10 mu Ci after the gold nanoclusters are attached to the wall 177 Lu was added to the well plates and co-cultured with the cells for 24 hours. The original medium was then discarded, washed 2 times with PBS, 100. Mu.L of complete medium for culturing 4T1 cells and 25. Mu.L of 253- (4,5-dimethylthiazole-2) -2,5-diphenyltetrazolium bromide solution (MTT, 5 mg/mL) were added and incubated for 4 hours, 100. Mu.L of DMSO was added to each well after carefully aspirating the supernatant, the crystals were dissolved sufficiently by shaking after incubation for 10 minutes, and the absorbance at 490nm wavelength was measured for each well using a microplate reader to evaluate the cell activity.
As can be seen from the figure 5 of the drawings, 177 lu @ AuNCs has better killing effect, and has the killing effect of 88.86% when the activity is only 10 mu Ci, but the activity is free 177 The killing effect of Lu is only 8.99-15.92%. This provides the basis for anti-tumor in mice.
As can be seen from FIG. 5, nuclide-labeled gold nanoclusters having activities of 0, 0.313. Mu. Ci, 0.613. Mu. Ci, 1.25. Mu. Ci, 2.5. Mu. Ci, 5. Mu. Ci, and 10. Mu. Ci, respectively 177 The survival rates of the Lu corresponding 4T1 mouse breast cancer cells are 99.1379951, 97.04243145, 94.05513859, 86.94359813, 74.90525377, 34.73285279 and 11.14661514 respectively.
Application example 2: 177 anti-tumor effect of Lu-labeled gold nanoclusters in vivo
Mouse breast cancer cells (4T 1) are used for constructing a subcutaneous tumor model, and the subcutaneous tumor model and the intratumoral injection are respectively injected through tail veins once and intratumoral injection once 177 Lu @ AuNCs (tail vein: 200. Mu. Ci, intratumoral: 75. Mu. Ci) was treated in mice in vivo.
As can be seen from FIG. 6, the free form 177 Lu phase, after disposable tail vein administration 177 Lu @ AuNCs has good anti-tumor effect, and the effect of intratumoral injection is better than that of tail vein injection, and intratumoral injection 177 Lu @ AuNCs substantially completely inhibited tumor growth.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (5)
1. A kind of 177 The preparation method of the Lu-labeled gold nanoclusters is characterized by comprising the following steps of:
1) Reducing chloroauric acid by using glutathione to obtain gold nanoclusters;
2) By using 177 LuCl 3 The gold nanoclusters are marked by hydrochloric acid eluent to obtain 177 Lu-labeled gold nanoclusters;
the molar ratio of the glutathione to the chloroauric acid in the step 1) is 3 to 5 to 4 to 6, the glutathione is a glutathione aqueous solution, and the chloroauric acid is a chloroauric acid aqueous solution;
the concentration of the glutathione aqueous solution is 40 to 60mg/mL, and the concentration of the chloroauric acid aqueous solution is 0.5 to 1.5 mol/L;
the temperature of the reduction in the step 1) is 80-100 ℃, and the time is 25-40 min;
step 2) the 177 LuCl 3 The activity of the hydrochloric acid eluent is 1 to 3mCi, the concentration of the gold nanocluster is 30 to 40mg/mL, and the gold nanocluster is prepared from the hydrochloric acid eluent 177 LuCl 3 The volume ratio of the hydrochloric acid eluent to the gold nanoclusters is 3 to 50-100;
step 2) the marking 177 LuCl 3 The pH value of the hydrochloric acid eluent is adjusted to 5~6, and then the gold nanoclusters are marked for 20-40 min.
2. The production method according to claim 1, wherein the reaction solution is filtered after the reduction in step 1), and the gold nanoclusters are obtained by centrifugal concentration after the pH of the filtrate is adjusted to 2~5.
3. The method of claim 1 or 2 177 Prepared by the method for preparing Lu-marked gold nanocluster 177 Lu-labeled gold nanoclusters.
4. The method of claim 3 177 The application of the Lu-marked gold nanoclusters in preparing antitumor drugs.
5. The use of claim 4, wherein the tumor is 4T1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010803689.7A CN111906328B (en) | 2020-08-11 | 2020-08-11 | A kind of 177 Lu-labeled gold nanocluster and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010803689.7A CN111906328B (en) | 2020-08-11 | 2020-08-11 | A kind of 177 Lu-labeled gold nanocluster and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111906328A CN111906328A (en) | 2020-11-10 |
| CN111906328B true CN111906328B (en) | 2022-10-25 |
Family
ID=73283101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010803689.7A Active CN111906328B (en) | 2020-08-11 | 2020-08-11 | A kind of 177 Lu-labeled gold nanocluster and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111906328B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114073780A (en) * | 2020-08-21 | 2022-02-22 | 上海交通大学 | Metal nanocluster containing radioactive metal nuclide, nanomaterial, preparation method of metal nanocluster and nanomaterial and application of metal nanocluster and nanomaterial in preparation of targeted drug |
| CN113730613B (en) * | 2021-09-09 | 2022-03-29 | 苏州大学 | Application of lutetium-labeled nano-carrier in preparation of medicine for treating neuroendocrine tumor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105936820A (en) * | 2016-04-20 | 2016-09-14 | 北京工商大学 | Water soluble biocompatible fluorescent magnetic nanoclusters and preparation method thereof |
| WO2020065115A2 (en) * | 2018-09-26 | 2020-04-02 | Nanogap Sub-Nm-Powder, S.A. | Therapeutic uses of atomic quantum clusters |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110111002A1 (en) * | 2009-11-12 | 2011-05-12 | Calin Viorel Pop | Transport and delivery of glutathione into human cells using gold nanoparticles |
| EP3237016A1 (en) * | 2014-12-23 | 2017-11-01 | Midatech Ltd | Nanoparticles and their use in cancer therapy |
| WO2016164578A1 (en) * | 2015-04-07 | 2016-10-13 | Memorial Sloan Kettering Cancer Center | Nanoparticle immunoconjugates |
| AU2016268064B2 (en) * | 2015-05-22 | 2021-07-22 | Board Of Regents, The University Of Texas System | Radioactive nanoparticles and methods of making and using the same |
| CN107684560B (en) * | 2016-08-05 | 2021-05-11 | 深圳深见医药科技有限公司 | Application of substance containing gold clusters in preparation of medicine for preventing and treating Alzheimer disease |
| CN107971481B (en) * | 2016-10-21 | 2022-01-25 | 国家纳米科学中心 | Gold nanocluster with antibacterial activity and preparation method and application thereof |
| JP2020520953A (en) * | 2017-05-25 | 2020-07-16 | メモリアル スローン ケタリング キャンサー センター | Zirconium-89 labeled ultra-small nanoparticles and methods thereof |
-
2020
- 2020-08-11 CN CN202010803689.7A patent/CN111906328B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105936820A (en) * | 2016-04-20 | 2016-09-14 | 北京工商大学 | Water soluble biocompatible fluorescent magnetic nanoclusters and preparation method thereof |
| WO2020065115A2 (en) * | 2018-09-26 | 2020-04-02 | Nanogap Sub-Nm-Powder, S.A. | Therapeutic uses of atomic quantum clusters |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111906328A (en) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111906328B (en) | A kind of 177 Lu-labeled gold nanocluster and preparation method and application thereof | |
| Al-Yasiri et al. | Mangiferin functionalized radioactive gold nanoparticles (MGF-198 AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy | |
| US5762903A (en) | Radioactive chitosan complex for radiation therapy | |
| KR102225239B1 (en) | Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer | |
| EA011715B1 (en) | Liposomes enclosing a radioactive isotope and a cytotoxic agent for combination therapy | |
| Di Pasqua et al. | Tumor accumulation of neutron-activatable holmium-containing mesoporous silica nanoparticles in an orthotopic non-small cell lung cancer mouse model | |
| Sakr et al. | 99mTc-gallic-gold nanoparticles as a new imaging platform for tumor targeting | |
| Park et al. | Synthesis of 64Cu-radiolabeled folate-conjugated iron oxide nanoparticles for cancer diagnosis | |
| US7803350B2 (en) | Radioactive arsenic-containing compounds and their uses in the treatment of tumors | |
| CN102671220B (en) | Radioactive anion resin microsphere and method for preparing same | |
| EP0730871B1 (en) | Radioactive chitosan complex and the use thereof for radiation therapy | |
| WO2018028643A1 (en) | Medical phosphorus-32 carbon microsphere and preparation method therefor | |
| CN102671219B (en) | Radioactive anion resin microsphere and preparation method (1) thereof | |
| CN108144074A (en) | Melanin nano particle, hydrogel and the preparation method of a kind of radioiodination, application | |
| Wu et al. | Facile preparation of 177Lu-microspheres for hepatocellular carcinoma radioisotope therapy | |
| WO2018028645A1 (en) | Medical yttrium-90 carbon microsphere, and preparation method therefor | |
| CN114306654A (en) | Application of dopamine in improvement of stability of radionuclide in radioactive microspheres | |
| Jeeves et al. | Studies of HPD and radiolabelled HPD in-vivo and in-vitro | |
| Valdovinos et al. | Auger electron-based targeted radioimmunotherapy with 58mCo, a feasibility study | |
| EP1477174B1 (en) | Radioactive arsenic-containing compounds and their uses in the treatment of tumors | |
| US10265426B2 (en) | Scandium nano-radiopharmaceutical | |
| KR100955665B1 (en) | Preparation method of 99mTc-labeled Fe2O3 nanoparticle and diagnostic imaging agents or therapeutic agents for cancer diseases comprising thereof | |
| España Palomares et al. | Zinc-doped iron oxide nanoparticles as a proton-activatable agent for dose range verification in proton therapy | |
| Yu-guo et al. | Synthesis of [14 C] quincetone | |
| Pham et al. | 153 Sm-labeled Fe 3 O 4@ lapatinib nanoparticles as a potential therapeutic agent for breast cancer: synthesis, quality control, and in vivo evaluation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |